NASDAQ: IMDXInsight Molecular Diagnostics Inc Stock
$2.91-0.12 (-3.96%)
Updated Jul 8, 2025
IMDX Price
$2.91
Fair Value Price
N/A
Market Cap
$83.22M
52 Week Low
$1.92
52 Week High
$4.75
P/E
-0.75x
P/B
8.14x
P/S
20.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.84M
Earnings
-$58.26M
Gross Margin
52.6%
Operating Margin
-1,513.51%
Profit Margin
-1,516.1%
Debt to Equity
4.91
Operating Cash Flow
-$23M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMDX Overview
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMDX's potential to beat the market
- IMDX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important IMDX news, forecast changes, insider trades & much more!
IMDX News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMDX is poor value based on its book value relative to its share price (8.14x), compared to the US Diagnostics & Research industry average (3.62x)
P/B vs Industry Valuation
IMDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IMDX due diligence checks available for Premium users.
Valuation
IMDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
20.59x
Market
30.75x
IMDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.14x
Industry
3.62x
IMDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMDX's financial health
Profit margin
Revenue
$2.1M
Net Income
-$6.7M
Profit Margin
-312%
IMDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$60.4M
Liabilities
$50.1M
Debt to equity
4.91
IMDX's short-term assets ($36.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMDX's long-term liabilities ($40.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
-$307.0k
Financing
$28.6M
IMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMDX vs Diagnostic & Research Stocks
Insight Molecular Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.